Skip to main content

Table 2 Patient Satisfaction With the Ovaleap® Pen at the End of Cycle 2

From: Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study

  

Previous Treatment in Main Study

Question

Total Group

Ovaleap®

Gonal-f®

 

N = 143

N = 77

N = 66

n (%)

n (%)

n (%)

Overall ease of usea

   

 Mean (SD)

1.4 (1.1)

1.2 (0.5)

1.5 (1.4)

Confidence about accurate dose

   

 Very confident

119 (83.2)

66 (85.7)

53 (80.3)

 Confident

24 (16.8)

11 (14.3)

13 (19.7)

 Not confident

0

0

0

Confidence about correct injection

  

 Very confident

120 (83.9)

67 (87.0)

53 (80.3)

 Confident

23 (16.1)

10 (13.0)

13 (19.7)

 Not confident

0

0

0

Plainness of instructional text

   

 Very easy

108 (75.5)

58 (75.3)

50 (75.8)

 Easy

34 (23.8)

19 (24.7)

15 (22.7)

 Not easy

1 (0.7)

0

1 (1.5)

Frequency of explanation of administration

   

 Never

87 (60.8)

52 (67.5)

35 (53.0)

 Once

54 (37.8)

25 (32.5)

29 (43.9)

 Twice

2 (1.4)

0

2 (3.0)

Convenience of pen usage

   

 Very convenient

110 (76.9)

56 (72.7)

54 (81.8)

 Convenient

33 (23.1)

21 (27.3)

12 (18.2)

 Not convenient

0

0

0

Satisfaction with administration

   

 Very satisfied

119 (83.2)

63 (81.8)

56 (84.8)

 Satisfied

24 (16.8)

14 (18.2)

10 (15.2)

 Not satisfied

0

0

0

  1. aThe overall ease of use of the pen was rated using a scale ranging from 1 (easiest) to 10 (most difficult)